Valuation: Nanosonics Limited

Market Cap 937M 656M 570M 532M 488M 921M 62.49B 6.27B 2.46B 31.16B 2.46B 2.41B 103B P/E 2026 *
59.1x
P/E 2027 * 43.3x
Enterprise Value 776M 543M 472M 441M 405M 763M 51.77B 5.2B 2.04B 25.82B 2.04B 2B 85.16B EV / Sales 2026 *
3.68x
EV / Sales 2027 * 3.32x
Free-Float
82.89%
Yield 2026 *
-
Yield 2027 * -
1 day+0.23%
1 month-14.12%
3 months-5.19%
6 months-12.40%
Current year-24.48%
1 month 2.18
Extreme 2.185
2.19
Current year 2.01
Extreme 2.01
3
1 year 2.01
Extreme 2.01
3.06
3 years 1.69
Extreme 1.69
3.3
5 years 1.69
Extreme 1.69
5.16
10 years 0
Extreme 0
6.17
Manager TitleAgeSince
Chief Executive Officer - 21/10/2013
Director of Finance/CFO - 03/10/2023
Chief Tech/Sci/R&D Officer - 01/09/2023
Director TitleAgeSince
Director/Board Member - 30/07/2012
Chairman 64 01/07/2022
Director/Board Member 70 24/10/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.23%-.--% - - 649M
-0.05%+2.59%+23.03%+4.68% 212B
+1.29%+0.51%+0.02%-23.29% 137B
+6.25%+5.21%-22.33%+20.60% 125B
+3.64%+6.42%-54.65%-4.82% 69.46B
+3.20%+6.96%+10.90%+11.02% 49.56B
+6.10%+11.55%-15.77%-20.80% 47.2B
+1.03%+1.39%+21.73%+11.80% 39.08B
-0.68%+0.95%+31.22%+28.60% 37.05B
-3.38%+4.59%+101.30%+6.92% 30.97B
Average +2.17%+3.19%+10.61%+3.86% 83.06B
Weighted average by Cap. +2.72%+2.80%+4.35%+1.79%

Financials

2026 *2027 *
Net sales 211M 147M 128M 120M 110M 207M 14.06B 1.41B 553M 7.01B 554M 542M 23.12B 230M 161M 140M 130M 120M 226M 15.31B 1.54B 602M 7.64B 604M 590M 25.19B
Net income 16.52M 11.56M 10.05M 9.38M 8.61M 16.24M 1.1B 111M 43.33M 550M 43.43M 42.47M 1.81B 22.78M 15.94M 13.85M 12.93M 11.87M 22.39M 1.52B 153M 59.73M 758M 59.88M 58.55M 2.5B
Net Debt -161M -112M -97.66M -91.18M -83.7M -158M -10.71B -1.08B -421M -5.34B -422M -413M -17.62B -175M -122M -106M -99.36M -91.21M -172M -11.67B -1.17B -459M -5.82B -460M -450M -19.2B
Logo Nanosonics Limited
Nanosonics Limited is an Australia-based infection prevention company. The Company's principal activities include the manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories. It is focused on the research, development, and commercialization of infection control and decontamination products and related technologies. Trophon technology includes high-frequency ultrasonic vibrations that generate a sonically activated hydrogen peroxide (H2O2) mist that kills bacteria, fungi, and viruses. Its products include trophon2, Nanosonics Auditpro, and trophon EPR. Its trophon2 includes AcuTrace radio frequency identification (RFID) technology, which enables digital record keeping and captures disinfection data. Nanosonics AuditPro is an automated digital system that combines clinician infection prevention decision making, with the Trophon 2 device infection control workflow data, and patient procedure information.
Employees
470
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.180AUD
Average target price
4.265AUD
Spread / Average Target
+34.12%

Quarterly revenue - Rate of surprise